CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 69 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $63,658 | -57.8% | 52,179 | -24.6% | 0.00% | -100.0% |
Q1 2024 | $150,810 | +33.0% | 69,179 | -5.5% | 0.00% | 0.0% |
Q4 2023 | $113,427 | +20.2% | 73,179 | 0.0% | 0.00% | 0.0% |
Q3 2023 | $94,401 | -25.3% | 73,179 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $126,451 | +14.4% | 73,179 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $110,500 | +76.1% | 73,179 | -12.0% | 0.00% | -66.7% |
Q4 2022 | $62,753 | -48.1% | 83,179 | 0.0% | 0.00% | +200.0% |
Q3 2022 | $121,000 | -21.9% | 83,179 | -1.2% | 0.00% | 0.0% |
Q2 2022 | $155,000 | -30.8% | 84,179 | 0.0% | 0.00% | -50.0% |
Q1 2022 | $224,000 | -38.6% | 84,179 | 0.0% | 0.00% | -33.3% |
Q4 2021 | $365,000 | -42.4% | 84,179 | -32.3% | 0.00% | -25.0% |
Q3 2021 | $634,000 | +18.9% | 124,356 | +47.7% | 0.00% | -20.0% |
Q2 2021 | $533,000 | -19.0% | 84,179 | -1.2% | 0.01% | -16.7% |
Q1 2021 | $658,000 | +15.2% | 85,179 | -2.3% | 0.01% | 0.0% |
Q4 2020 | $571,000 | -29.9% | 87,175 | -21.6% | 0.01% | -45.5% |
Q3 2020 | $815,000 | -26.5% | 111,178 | -16.5% | 0.01% | -26.7% |
Q2 2020 | $1,109,000 | +2.4% | 133,177 | -5.7% | 0.02% | -25.0% |
Q1 2020 | $1,083,000 | -8.3% | 141,177 | -0.7% | 0.02% | +11.1% |
Q4 2019 | $1,181,000 | +19.2% | 142,177 | -0.1% | 0.02% | +20.0% |
Q3 2019 | $991,000 | -40.0% | 142,270 | -3.4% | 0.02% | -50.0% |
Q2 2019 | $1,652,000 | -29.3% | 147,270 | -9.7% | 0.03% | -34.8% |
Q1 2019 | $2,337,000 | -5.2% | 163,177 | -0.1% | 0.05% | -22.0% |
Q4 2018 | $2,465,000 | -18.4% | 163,260 | +0.1% | 0.06% | -4.8% |
Q3 2018 | $3,019,000 | -21.4% | 163,177 | -1.2% | 0.06% | -1.6% |
Q2 2018 | $3,843,000 | -8.4% | 165,231 | -10.8% | 0.06% | -64.4% |
Q4 2017 | $4,194,000 | +14.6% | 185,187 | 0.0% | 0.18% | +94.5% |
Q3 2017 | $3,661,000 | +123.2% | 185,187 | +85.2% | 0.09% | +106.8% |
Q2 2017 | $1,640,000 | -51.1% | 100,000 | -49.3% | 0.04% | -53.2% |
Q1 2017 | $3,356,000 | +42.4% | 197,177 | -7.5% | 0.09% | +22.1% |
Q4 2016 | $2,357,000 | -28.3% | 213,177 | +0.5% | 0.08% | -42.5% |
Q3 2016 | $3,287,000 | +47.3% | 212,189 | -3.4% | 0.13% | +48.9% |
Q2 2016 | $2,232,000 | – | 219,689 | – | 0.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Canaan Partners IX LLC | 4,244,381 | $43,378,000 | 100.00% |
VHCP Management II, LLC | 577,831 | $5,905,000 | 3.56% |
REGENTS OF THE UNIVERSITY OF CALIFORNIA | 71,366 | $729,000 | 2.45% |
Casdin Capital, LLC | 234,179 | $2,392,000 | 2.38% |
BVF INC/IL | 606,138 | $6,192,000 | 1.32% |
Opaleye Management Inc. | 160,000 | $1,634,000 | 1.09% |
Redmile Group, LLC | 733,899 | $7,497,000 | 0.72% |
VHCP Management, LLC | 64,200 | $656,000 | 0.68% |
Montecito Bank & Trust | 146,544 | $1,497,000 | 0.63% |
Cormorant Asset Management, LP | 371,636 | $3,796,000 | 0.54% |